• Priyanka Maurya Kailash institute of pharmacy and management gida, Gorakhpur, India
  • Kirti Gupta Kailash institute of pharmacy and management gida, Gorakhpur, India
  • Ashutosh Kushwaha Kailash institute of pharmacy and management gida, Gorakhpur, India.
  • Dr Jai Narayan Mishra Kailash institute of pharmacy and management gida, Gorakhpur, India.
Keywords: Liposomes, Advance Drug Delivery, Drug targeting, Nanotechnology


When a self-forming enclosed lipid bi-layer was hydrated, the liposome or lipid vesicle was discovered. Liposome drug delivery systems have played a key role in the development of powerful drugs that have improved therapies Liposome formulations have recently been aimed at reducing toxicity and increasing accumulation at the target site The suppression of rapid liposome clearance by regulating particle size, charge, and surface hydration is one of several new liposome manufacturing methods based on lipid drug interactions and liposome disposition mechanisms. Targeting tissue with or without expression of target recognition molecules on the lipid membrane is the most common clinical use of liposomal drug delivery. Physical, chemical, and biological factors are used to characterise the liposomes. Liposome size is another important metric that helps describe the liposome, which is normally done by successive extrusion at different temperatures. Several groups of medications, such as antiviral, antifungal, antibacterial, vaccines, anti-tubercular therapies, and gene treatments, benefit from this route of drug delivery since it increases their safety and efficacy. Liposomes are now used in immunology, dermatology, vaccine adjuvant, eye problems, brain targeting, infectious disease, and cancer therapy. The particular binding properties of a drug-carrying liposome to a target cell, such as a tumour cell, and certain substances in the body (antibodies, proteins, peptides, and so on) are recent breakthroughs in this field; stealth liposomes, which are notably being exploited as carriers for hydrophilic drugs (water soluble) anticancer drugs like doxorubicin, mitoxantrone; and bisphosphonate- liposome mediated depletion of macrophages. This review would be a help to the researchers working in the area of liposomal drug delivery.


Download data is not yet available.


Alving C.R. Macrophages, as targets for delivery of liposome encapsulated antimicrobial agents. Adv Delivery Rev, (1998); 2.

C. J. Chapman Allison, Gregoriadis, G, 1974. Liposomes as immunological adjuvant. Nature 252, 252.

Bangham A.D., editor. The Liposome Letters. Academic Press; 1983.

Ehrlich, P. The relations existing between chemical constitution, distribution and pharmacological action. In Ehrlich, P. (Ed.), Collected Studies on Immunity, Vol. 2, Wiley, New York, 1906, pp. 404 443.

Kimball's Biology Pages, "Cell Membranes." Stryer S. Biochemistry, 1981, 213.

Vyas S.P. & Khar R.K. “Targeted & controlled drug delivery: Novel carrier system”. CBS publishers and distributors, 2007.

Yan Chen, Qingqing Wu, Zhenghai Zhang, Ling Yuan, Xuan Liu and Lei Zhou “Preparation of CurcuminLoaded Liposomes and Evaluation of Their Skin Permeation and Pharmacodynamics “ Molecules 2012, 17, 5972-5987.

H.A.H Rongen, A. Bult and W.P van Bennekom. J. Immuno. Methods, (1997) 204:105-133.

New, R.R.C., Preparation of liposomes. In: New, R.R.C.(Ed.), Lipsomes: a practical approach, IRL Press, Oxford,1990, pp. 33 104.

Jr. F. Szoka and D. Papahadjopoulos. Proc. Natl. Acad. Sci. USA, (1978) 60:4194-4198.

Jain N.K. Controlled and Novel Drug Delivery. CBS Publisher, Page no. 304-326.

Kersten, G.F.A., Crommelin, D.J.A., 1995. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta 1241, 117-138.

K. Horton. Disertation for degree of Advanced Studies in Chemical Engineering, Universitat Rovira I Virgili, 2003.

Remington. The Science and Practice of Pharmacy. Volume I, 21st Edition, B.I Publishers Pvt Ltd, Page no. 314-316.

Shargel Leon. Applied Biopharmaceutics and Pharmacokinetics. 5 th no 214-218

Sharma. A. and Sharma Liposomes in drug delivery progress and Limitations. Int no 123,134-139.

Sharma, A., Straubinger, R.M., 1994. Novel taxol formulations:preparation and characterization of taxol-containingliposomes. Pharm. Res. 11, 889 896

Szoka, F.C., Liposomal drug delivery: current status and future prospects. In: Wilschut, J., Hoekstra, D. (Eds.),Membrane Fusion, Marcel Dekker, New York, 1991, pp.845-890.

Vingerhoeds, M.H., Storm, G. and Crommelin, D.J.A. Immunomethods (1994) 4:259–272. 20. Vyas S.P. & Khar R.K. Targeted and Controlled Drug Delivery, Novel carrier system. 1st edition, CBS Publisher, 173-206

Deamer, D. and Uster, P., LIPOSOME PREPARATION METHODA AND monitoring liposome fusion. In: Baserga, R., Croce, C. and Royeza, G (Eds), Introduction of Macromolecules into viable Mammalian Cells, Alan R. Liss, New York, 1980,pp. 205 220.

Deamer D. and Bangham A.D. Biochim. Biophys. Acta.; 1976; 443: 629. 5. Gomez-Hens, A., Fernandez-Romero, J.M. “Analytical methods for the control of liposomal delivery systems”, Trends Anal Chem, 2006, 25,167–178.

Perrett S, Golding M, Williams WP. “A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. “ J Pharm Pharmacol. 1991 Mar; 43(3):154-61.

Bhalerao SS, Raje Harshal A. “Preparation, optimization, characterization, 3. Churchill L, Graham A, Shih C-K, et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Boehringer Inand stability studies of salicylic acid liposomes” Drug Dev Ind Pharm. 2003 Apr (4); 453-459

Gregoriadis G, Florene A.T. Liposomes in Drug Delivery: Clinical, Diagnostic andOpthalmic Potential. Drugs 1993;45 15-2

Van Rooijen N, van Nieuwmegen R. Liposomes in Immunology: MultilammellarPhosphatidylcholine Liposome as a Simple Biodegradable and Harmless 26. Adjuvantwithout any Immunogenic Activity of its Own. Immunology Community 1980;9243-356

Campbell P.I. Toxicity of Some Charged Lipids Used in Liposome Preparations. Cytobios1983;37 (1983) 21-26.

Grislain L, Couvreur P, Lenaerts V, Roland M, Depreg-Decampeneere D, Speiser P.Pharmacokinetics andDistribution of a Biodegradable Drug-carrier. InternationalJournal of Pharmacology 1983;15 335-338.

Illum L, Gones P.D.E, Kreuker J, Daldwin R.W, Davis D.D. Adsorption of MonoclonalAntibodies toPolyhexylcyanoacrylate Nanoparticles and Subsequent ImmunospecificBinding to Tumor Cells. InternationalJournal of Pharmacology 1983;1765-69.

Hashida M, Takahashi Y, Muranishi S, Sezaki H. An Application of Water in Oil andGelatinMirosphere in Oil Emulsions to Specific Delivery of Anticancer Agents intoStomach Lymphatics. Journal of Pharmacokinetics and Biopharmacetics 1977;5241-144.

Mizushima Y, Hamano T, Yokohama K. Use of a Lipid Emulsion as a Novel Carrierfor Corticosteriods. Journal of Pharmacology and Pharmacotherapeutics 1982;3449-53

How to Cite
Maurya, P., Gupta, K., Kushwaha, A., & Mishra, D. J. N. (2021). PHARMACEUTICAL LIPOSOMAL DRUG DELIVERY: A COMPLETE REVIEW OF NEW DELIVERY SYSTEM. IJRDO - Journal of Biological Science (ISSN: 2455-7676), 7(8), 01-12. Retrieved from